UK Supreme Court Ruling on Deeming Fictions and Tax Treaty Interpretation
In: BLOOMBERG, BUREAU OF NATIONAL AFFAIRS, INC. (2020)
15 Ergebnisse
Sortierung:
In: BLOOMBERG, BUREAU OF NATIONAL AFFAIRS, INC. (2020)
SSRN
In: NLIU Law Review, 2011
SSRN
In: Verfassung und Recht in Übersee: VRÜ = World comparative law : WCL, Band 44, Heft 4, S. 602-615
ISSN: 0506-7286
In: Verfassung und Recht in Übersee: VRÜ = World comparative law : WCL, Band 44, Heft 4, S. 602-615
ISSN: 0506-7286
In: World Comparative Law (Verfassung und Recht in Ubersee), (2011) Vol. 44, No. 4 (Nomos Publishers, Germany)
SSRN
In: Asia Pacific Journal on Human Rights and the Law, Band 11, Heft 1, S. 23-38
SSRN
In: Stanford D. school Library
In: Tax Notes International (Forthcoming)
SSRN
In: Tax Notes International, Volume 100, Issue 2, October 12, 2020
SSRN
In: 11 NUJS L. Rev. 1 (2018)
SSRN
Working paper
In: Crime Punishment and Law - An International Journal, Band 2, Heft 1-2, S. 17-30
SSRN
In: Foreign affairs, Band 100, Heft 1, S. 98-110
ISSN: 0015-7120
World Affairs Online
In: NBER Working Paper No. w28541
SSRN
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download ; Drug-induced liver injury (DILI) is a complication of treatment with antituberculosis (TB) drugs, especially in isoniazid (INH)-containing regimens. To investigate genetic risk factors, we performed a genomewide association study (GWAS) involving anti-TB DILI cases (55 Indian and 70 European) and controls (1,199 Indian and 10,397 European). Most cases were treated with a standard anti-TB drug regimen; all received INH. We imputed single nucleotide polymorphism and HLA genotypes and performed trans-ethnic meta-analysis on GWAS and candidate gene genotypes. GWAS found one significant association (rs117491755) in Europeans only. For HLA, HLA-B*52:01 was significant (meta-analysis odds ratio (OR) 2.67, 95% confidence interval (CI) 1.63-4.37, P = 9.4 × 10-5 ). For N-acetyltransferase 2 (NAT2), NAT2*5 frequency was lower in cases (OR 0.69, 95% CI 0.57-0.83, P = 0.01). NAT2*6 and NAT2*7 were more common, with homozygotes for NAT2*6 and/or NAT2*7 enriched among cases (OR 1.89, 95% CI 0.84-4.22, P = 0.004). We conclude HLA genotype makes a small contribution to TB drug-related DILI and that the NAT2 contribution is complex, but consistent with previous reports when differences in the metabolic effect of NAT2*5 compared with those of NAT2*6 and NAT2*7 are considered. ; International Serious Adverse Events Consortium Abbott Laboratories Amgen Daiichi Sankyo Company Limited GlaxoSmithKline Merck & Company Novartis Pfizer Roche Holding Sanofi-Aventis Takeda Pharmaceutical Company Ltd Wellcome Trust National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research Unit NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust University of Nottingham Instituto de Salud Carlos III European Union (EU) Instituto de Salud Carlos III Swedish Medical Products Agency Swedish Society of ...
BASE